Bisphosphonate Drug Holiday and Fracture Risk: Reviewing the Evidence

[1] Heckbert SR(2008)Use of alendronate and risk of incident atrial fibrillation in women Arch Intern Med 168 826-831

[2] Li G(2015)Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis J Bone Miner Res 30 2179-2187

[3] Cummings SR(2018)Hip fracture trends in the United States, 2002 to 2015 Osteoporos Int 29 717-722

[4] Smith NL(2010)Bisphosphonates for the treatment of osteoporosis: insights for clinicians Ther Adv Chronic Dis 1 115-128

[5] Psaty BM(2020)History of alendronate Bone 137 115411-2282

[6] Jha S(2012)Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2272-2050

[7] Wang Z(2006)Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis N Engl J Med 355 2048-353

[8] Laucis N(2007)Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution J Bone Joint Surg Br 89 349-1737

[9] Bhattacharyya T(2013)Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis J Bone Miner Res 28 1729-2294

[10] Lewiecki EM(2010)Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2267-23

[1] Heckbert SR(2008)Use of alendronate and risk of incident atrial fibrillation in women Arch Intern Med 168 826-831

[2] Li G(2015)Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis J Bone Miner Res 30 2179-2187

[3] Cummings SR(2018)Hip fracture trends in the United States, 2002 to 2015 Osteoporos Int 29 717-722

[4] Smith NL(2010)Bisphosphonates for the treatment of osteoporosis: insights for clinicians Ther Adv Chronic Dis 1 115-128

[5] Psaty BM(2020)History of alendronate Bone 137 115411-2282

[6] Jha S(2012)Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2272-2050

[7] Wang Z(2006)Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis N Engl J Med 355 2048-353

[8] Laucis N(2007)Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution J Bone Joint Surg Br 89 349-1737

[9] Bhattacharyya T(2013)Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis J Bone Miner Res 28 1729-2294

[10] Lewiecki EM(2010)Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2267-23